MedTrace Logo

Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms

NCT03429075 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2024-10-24

Study results available
· View outcomes & findings →

Summary

This is a randomised double-blind clinical trial. The aim is to compare the efficacy and mechanisms of action of psilocybin, the primary psychoactive substance in 'magic mushrooms', with the selective serotonin reuptake inhibitor (SSRI) escitalopram for major depressive disorder (MDD).

Conditions

  • Depressive Disorder, Major

Interventions

DRUG

Psilocybin + Placebo

Multiple dosing days psilocybin vs 6 weeks of daily placebo

DRUG

Psilocybin + Escitalopram

Multiple dosing days psilocybin vs 6 weeks of daily escitalopram

Sponsors & Collaborators

  • Alexander Mosely Charitable Trust

    collaborator OTHER

  • Imperial College London

    lead OTHER

Principal Investigators

  • David J Nutt, Medicine · Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-07
Primary Completion
2020-04-17
Completion
2020-10-17

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03429075 on ClinicalTrials.gov